Condition
Olverembatinib
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (1)
P 3 (1)
Trial Status
Recruiting1
Unknown1
Not Yet Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07178912Phase 2Not Yet Recruiting
Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
NCT07282093Phase 1Recruiting
Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment
NCT05311943Phase 3UnknownPrimary
Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs.
Showing all 3 trials